Reunion Neuroscience Inc.

Informe acción TSX:REUN

Capitalización de mercado: CA$16.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Reunion Neuroscience Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Reunion Neuroscience's earnings have been declining at an average annual rate of -68.5%, while the Biotechs industry saw earnings growing at 30% annually. Revenues have been growing at an average rate of 83.9% per year.

Información clave

-68.5%

Tasa de crecimiento de los beneficios

-4.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 51.1%
Tasa de crecimiento de los ingresos83.9%
Rentabilidad financiera-178.9%
Margen neton/a
Última actualización de beneficios31 Mar 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Here's Why Field Trip Health (TSE:FTRP) Must Use Its Cash Wisely

Aug 01
Here's Why Field Trip Health (TSE:FTRP) Must Use Its Cash Wisely

We're Keeping An Eye On Field Trip Health's (TSE:FTRP) Cash Burn Rate

Apr 03
We're Keeping An Eye On Field Trip Health's (TSE:FTRP) Cash Burn Rate

Could The Field Trip Health Ltd. (CSE:FTRP) Ownership Structure Tell Us Something Useful?

Jan 17
Could The Field Trip Health Ltd. (CSE:FTRP) Ownership Structure Tell Us Something Useful?

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Reunion Neuroscience. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

TSX:REUN Ingresos, gastos y beneficios (CAD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Mar 230-381313
31 Dec 225-743911
30 Sep 225-68409
30 Jun 225-57399
31 Mar 220-18117
31 Dec 211-20136
30 Sep 211-22135
30 Jun 211-24134
31 Mar 211-23134
31 Dec 200-1693
30 Sep 200-962
30 Jun 200-541
31 Mar 200-330

Ingresos de calidad: REUN is currently unprofitable.

Margen de beneficios creciente: REUN is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Insufficient data to determine if REUN's year-on-year earnings growth rate was positive over the past 5 years.

Acelerando crecimiento: Unable to compare REUN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: REUN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.6%).


Rentabilidad financiera

Alta ROE: REUN has a negative Return on Equity (-178.92%), as it is currently unprofitable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado